{"id":250248,"date":"2012-03-15T15:14:30","date_gmt":"2012-03-15T15:14:30","guid":{"rendered":"http:\/\/www.eugenesis.com\/bioheart-and-ageless-partner-to-advance-stem-cell-field-with-laboratory-training-programs\/"},"modified":"2012-03-15T15:14:30","modified_gmt":"2012-03-15T15:14:30","slug":"bioheart-and-ageless-partner-to-advance-stem-cell-field-with-laboratory-training-programs","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/bioheart-and-ageless-partner-to-advance-stem-cell-field-with-laboratory-training-programs.php","title":{"rendered":"Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs"},"content":{"rendered":"<p><p>    SUNRISE, Fla., March 15, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc.    (BHRT.OB) announced today that it has successfully conducted a    laboratory training course in partnership with the Ageless Regenerative    Institute, an organization dedicated to the    standardization of cell regenerative medicine. The attendees    participated in hands on, in depth training in laboratory    practices in stem cell science.  <\/p>\n<p>    \"We had students from all over the world attend this first    course including physicians, laboratory technicians and    students,\" said Mike Tomas, Bioheart's President and CEO.    \"Bioheart is pleased to be able to share our 13 years of    experience in stem cell research and help expand    this growing life science field.\"  <\/p>\n<p>    The course included cell culture techniques and quality control    testing such as flow cytometry and gram stain. In addition,    participants learned how to work in a cleanroom operating    according to FDA cGMP standards, regulations used in the    manufacture of pharmaceuticals, food and medical devices.    Aseptic techniques were also taught as well as cleanroom    gowning, environmental monitoring and maintenance.  <\/p>\n<p>    Future courses are open to physicians, laboratory technicians    and students. After graduating the course, attendees are    prepared to pursue research and careers in the field of stem    cells and regenerative medicine. For more information about the    course, contact     <a href=\"mailto:info@agelessregen.com\">info@agelessregen.com<\/a>.  <\/p>\n<p>    About Bioheart, Inc.  <\/p>\n<p>    Bioheart is committed to maintaining its leading position    within the cardiovascular sector of the cell technology    industry delivering cell therapies and biologics that help    address congestive heart failure, lower limb ischemia, chronic    heart ischemia, acute myocardial infarctions and other issues.    Bioheart's goals are to cause damaged tissue to be regenerated,    when possible, and to improve a patient's quality of life and    reduce health care costs and hospitalizations.  <\/p>\n<p>    Specific to biotechnology, Bioheart is focused on the    discovery, development and, subject to regulatory approval,    commercialization of autologous cell therapies for the    treatment of chronic and acute heart damage and peripheral    vascular disease. Its leading product, MyoCell, is a clinical    muscle-derived cell therapy designed to populate regions of    scar tissue within a patient's heart with new living cells for    the purpose of improving cardiac function in chronic heart    failure patients. For more information on Bioheart, visit        <a href=\"http:\/\/www.bioheartinc.com\" rel=\"nofollow\">http:\/\/www.bioheartinc.com<\/a>.  <\/p>\n<p>    About Ageless Regenerative Institute, LLC  <\/p>\n<p>    The Ageless Regenerative Institute (ARI) is an organization    dedicated to the standardization of cell regenerative medicine.    The Institute promotes the development of evidence-based    standards of excellence in the therapeutic use of    adipose-derived stem cells through education, advocacy, and    research. ARI has a highly experienced management team with    experience in setting up full scale cGMP stem cell    manufacturing facilities, stem cell product development &    enhancement, developing point-of-care cell production systems,    developing culture expanded stem cell production systems, FDA    compliance, directing clinical & preclinical studies with    multiple cell types for multiple indications, and more. ARI has    successfully treated hundreds of patients utilizing these    cellular therapies demonstrating both safety and efficacy. For    more information about regenerative medicine please visit        <a href=\"http:\/\/www.agelessregen.com\" rel=\"nofollow\">http:\/\/www.agelessregen.com<\/a>.  <\/p>\n<p>    Forward-Looking Statements: Except for historical matters    contained herein, statements made in this press release are    forward-looking statements. Without limiting the generality of    the foregoing, words such as \"may,\" \"will,\" \"to,\" \"plan,\"    \"expect,\" \"believe,\" \"anticipate,\" \"intend,\" \"could,\" \"would,\"    \"estimate,\" or \"continue\" or the negative other variations    thereof or comparable terminology are intended to identify    forward-looking statements.  <\/p>\n<\/p>\n<p>Read more here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/bioheart-ageless-partner-advance-stem-110000855.html\" title=\"Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs\">Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SUNRISE, Fla., March 15, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that it has successfully conducted a laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the standardization of cell regenerative medicine.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/bioheart-and-ageless-partner-to-advance-stem-cell-field-with-laboratory-training-programs.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25],"tags":[],"class_list":["post-250248","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/250248"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=250248"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/250248\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=250248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=250248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=250248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}